-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KKq5Y6t3fdBF2e7VdMb2VNIU344vZ3cMCcbIVuL5K5q0RBecXnnF2JgzEWIBd0b2 ZA9CmuoretHCPkFtKg4AcQ== 0001048477-01-500070.txt : 20020413 0001048477-01-500070.hdr.sgml : 20020413 ACCESSION NUMBER: 0001048477-01-500070 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20011217 ITEM INFORMATION: Other events FILED AS OF DATE: 20011217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 1815782 BUSINESS ADDRESS: STREET 1: 371 BEL MARIN KEYS BLVD STREET 2: STE 210 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4158846700 MAIL ADDRESS: STREET 1: 371 BEL MARIN KEYS BLVD STREET 2: STE 210 CITY: NOVATO STATE: CA ZIP: 94949 8-K 1 form8k121701.txt ================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 17, 2001 (Date of earliest event reported): (December 13, 2001) BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number Identification No.) 371 Bel Marin Keys Boulevard, Suite 210, Novato, California 94949 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (415) 884-6700 Not Applicable ---------------- (Former name or former address, if changed since last report) ================================================================================ Item 5. Other Events On December 13, 2001, we announced the completion of a $96.6 million public offering of 8,050,000 shares of our common stock in a press release dated December 13, 2001. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7. Financial Statements and Exhibits EXHIBIT NO. DESCRIPTION OF DOCUMENT - ------------- ------------------------------------------------------------------ 99.1 Press Release Dated December 13, 2001 Related to the Announcement of the completion of a $96.6 Million Public Offering of Common Stock. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioMarin Pharmaceutical Inc. By: /s/ Raymond W. Anderson -------------------------------------------------- Raymond W. Anderson Chief Operating Officer, Chief Financial Officer, Secretary and Vice President Finance and Administration Date: December 17, 2001 Exhibit Index EXHIBIT NO. DESCRIPTION OF DOCUMENT - ------------- ------------------------------------------------------------------ 99.1 Press Release Dated December 13, 2001 Related to the Announcement of the completion of a $96.6 Million Public Offering of Common Stock. -----END PRIVACY-ENHANCED MESSAGE-----